Literature DB >> 3539994

Identification with monoclonal antibodies of hemolysin produced by clinical isolates of Escherichia coli.

F Hugo, M Arvand, J Reichwein, N Mackman, I B Holland, S Bhakdi.   

Abstract

Murine monoclonal antibodies were generated against the 107,000-dalton hemolysin encoded by the hemolytic determinant from Escherichia coli LE 2001, and colony blotting was used to assay for production of the hemolysin by 35 hemolytic strains of E. coli and other hemolytic members of the family Enterobacteriaceae of clinical origin. All hemolytic E. coli strains gave positive reactions with two monoclonal antibodies. In contrast, none of the hemolytic, non-E. coli isolates yielded positive colony blots. In addition, Western blotting showed that the hemolysins produced by all clinical E. coli isolates had a similar molecular weight of about 107,000. Discrete antigenic variation may occur in the molecule, since a third monoclonal antibody did not react with the hemolysin from a number of wild-type E. coli strains. Western blot analysis was used to assess the presence of immunoglobulin G (IgG), IgA, and IgM antibodies to E. coli hemolysin in human sera. All 20 of the tested sera from healthy adults contained antibodies to the toxin, with various constellations among the antibody classes. In contrast, sera from five of eight infants aged 8 to 36 months contained no antihemolysin antibodies. We conclude that the 107,000-dalton hemolysin of E. coli is a widespread immunogen that is produced by most or all hemolytic E. coli strains in the human host.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3539994      PMCID: PMC265810          DOI: 10.1128/jcm.25.1.26-30.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Properties of strains of Escherichia coli isolated from a variety of sources.

Authors:  E M Cooke; S P Ewins
Journal:  J Med Microbiol       Date:  1975-02       Impact factor: 2.472

Review 2.  Membrane damage by pore-forming bacterial cytolysins.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microb Pathog       Date:  1986-02       Impact factor: 3.738

3.  Functional characterization of a cloned haemolysin determinant from E. coli of human origin, encoding information for the secretion of a 107K polypeptide.

Authors:  N Mackman; I B Holland
Journal:  Mol Gen Genet       Date:  1984

4.  Hemolysin production as a virulence marker in symptomatic and asymptomatic urinary tract infections caused by Escherichia coli.

Authors:  C Hughes; J Hacker; A Roberts; W Goebel
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

5.  Transport of hemolysin across the outer membrane of Escherichia coli requires two functions.

Authors:  W Wagner; M Vogel; W Goebel
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

Review 6.  Escherichia coli alpha-hemolysin: characteristics and probable role in pathogenicity.

Authors:  S J Cavalieri; G A Bohach; I S Snyder
Journal:  Microbiol Rev       Date:  1984-12

7.  Virulence of urinary and faecal Escherichia coli in relation to serotype, haemolysis and haemagglutination.

Authors:  J F van den Bosch; P Postma; P A Koopman; J de Graaff; D M MacLaren; D G van Brenk; P A Guinée
Journal:  J Hyg (Lond)       Date:  1982-06

8.  Characterization of Escherichia coli hemolysins conferring quantitative differences in virulence.

Authors:  R A Welch; S Falkow
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

9.  In vivo function of hemolysin in the nephropathogenicity of Escherichia coli.

Authors:  C Waalwijk; D M MacLaren; J de Graaff
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

10.  Cloned hemolysin genes from Escherichia coli that cause urinary tract infection determine different levels of toxicity in mice.

Authors:  J Hacker; C Hughes; H Hof; W Goebel
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

View more
  16 in total

1.  Enterohemolysin production is associated with a temperate bacteriophage in Escherichia coli serogroup O26 strains.

Authors:  L Beutin; L Bode; M Ozel; R Stephan
Journal:  J Bacteriol       Date:  1990-11       Impact factor: 3.490

2.  Partial purification of alpha-hemolysin in Escherichia coli.

Authors:  F Nistiar; V Janigová; J Durovicová; H Puzová
Journal:  Folia Microbiol (Praha)       Date:  1991       Impact factor: 2.099

Review 3.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

4.  Rapid detection of Bordetella pertussis by a monoclonal antibody-based colony blot assay.

Authors:  B Gustafsson; P Askelöf
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

5.  Characterization of the roles of hemolysin and other toxins in enteropathy caused by alpha-hemolytic Escherichia coli linked to human diarrhea.

Authors:  S J Elliott; S Srinivas; M J Albert; K Alam; R M Robins-Browne; S T Gunzburg; B J Mee; B J Chang
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Quantitative study of the binding and hemolytic efficiency of Escherichia coli hemolysin.

Authors:  B Eberspächer; F Hugo; S Bhakdi
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

7.  Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7.

Authors:  M E Bauer; R A Welch
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

Review 8.  The hemolysin of Escherichia coli.

Authors:  S Bhakdi; N Mackman; G Menestrina; L Gray; F Hugo; W Seeger; I B Holland
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

Review 9.  Virulence factors in Escherichia coli urinary tract infection.

Authors:  J R Johnson
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

10.  Genetic conservation of hlyA determinants and serological conservation of HlyA: basis for developing a broadly cross-reactive subunit Escherichia coli alpha-hemolysin vaccine.

Authors:  P O'Hanley; R Marcus; K H Baek; K Denich; G E Ji
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.